|
US4160452A
(en)
|
1977-04-07 |
1979-07-10 |
Alza Corporation |
Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
|
|
US4256108A
(en)
|
1977-04-07 |
1981-03-17 |
Alza Corporation |
Microporous-semipermeable laminated osmotic system
|
|
US4265874A
(en)
|
1980-04-25 |
1981-05-05 |
Alza Corporation |
Method of delivering drug with aid of effervescent activity generated in environment of use
|
|
GR78491B
(enExample)
*
|
1982-03-24 |
1984-09-27 |
Nat Res Dev |
|
|
JPS60197684A
(ja)
|
1984-03-21 |
1985-10-07 |
Dainippon Pharmaceut Co Ltd |
ベンゾ〔ａ〕キノリジン誘導体およびその塩
|
|
US5007790A
(en)
|
1989-04-11 |
1991-04-16 |
Depomed Systems, Inc. |
Sustained-release oral drug dosage form
|
|
US5169645A
(en)
|
1989-10-31 |
1992-12-08 |
Duquesne University Of The Holy Ghost |
Directly compressible granules having improved flow properties
|
|
CA2132012C
(en)
|
1992-03-25 |
2003-04-22 |
John W. Shell |
Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
|
|
US5582837A
(en)
|
1992-03-25 |
1996-12-10 |
Depomed, Inc. |
Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
|
|
AU3290397A
(en)
|
1996-06-10 |
1998-01-07 |
Depomed, Inc. |
Gastric-retentive oral controlled drug delivery system with enhanced retention properties
|
|
US5972389A
(en)
|
1996-09-19 |
1999-10-26 |
Depomed, Inc. |
Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
|
|
WO1998033501A1
(en)
|
1997-01-31 |
1998-08-06 |
Avid Therapeutics Inc. |
2-benzoylamino-3-phenylpropenamide derivatives and methods of using the same
|
|
ATE302597T1
(de)
|
1997-06-06 |
2005-09-15 |
Depomed Inc |
Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung
|
|
US6635280B2
(en)
|
1997-06-06 |
2003-10-21 |
Depomed, Inc. |
Extending the duration of drug release within the stomach during the fed mode
|
|
ITFI970193A1
(it)
|
1997-08-01 |
1999-02-01 |
Applied Research Systems |
Uso di derivati benzo(c) chinolizinici come regolatori della crescita delle piante e composizioni ad uso agricolo che contengono tali
|
|
US6323219B1
(en)
|
1998-04-02 |
2001-11-27 |
Ortho-Mcneil Pharmaceutical, Inc. |
Methods for treating immunomediated inflammatory disorders
|
|
NZ518739A
(en)
|
1999-11-02 |
2004-12-24 |
Depomed Inc |
Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
|
|
MXPA02007254A
(es)
|
2000-02-04 |
2002-12-09 |
Depomed Inc |
Forma de dosis de cubierta-y-nucleo que se aproxima a liberacion de droga de orden cero.
|
|
US6488962B1
(en)
|
2000-06-20 |
2002-12-03 |
Depomed, Inc. |
Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
|
|
US6451808B1
(en)
|
2000-10-17 |
2002-09-17 |
Depomed, Inc. |
Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
|
|
WO2002096404A1
(en)
|
2001-05-29 |
2002-12-05 |
Depomed Development Ltd |
Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough
|
|
TWI232863B
(en)
|
2001-06-11 |
2005-05-21 |
Akzo Nobel Nv |
Benzoxazepine derivatives
|
|
US6723340B2
(en)
|
2001-10-25 |
2004-04-20 |
Depomed, Inc. |
Optimal polymer mixtures for gastric retentive tablets
|
|
CA2409552A1
(en)
|
2001-10-25 |
2003-04-25 |
Depomed, Inc. |
Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
|
|
TWI312285B
(en)
|
2001-10-25 |
2009-07-21 |
Depomed Inc |
Methods of treatment using a gastric retained gabapentin dosage
|
|
JP2005508358A
(ja)
|
2001-10-25 |
2005-03-31 |
デポメド・インコーポレイテッド |
胃滞留型ロサルタン投与量を用いる治療方法
|
|
US20030091630A1
(en)
|
2001-10-25 |
2003-05-15 |
Jenny Louie-Helm |
Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
|
|
US6682759B2
(en)
|
2002-02-01 |
2004-01-27 |
Depomed, Inc. |
Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
|
|
US7951789B2
(en)
|
2006-12-28 |
2011-05-31 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
|
WO2008130527A1
(en)
|
2007-04-18 |
2008-10-30 |
Merck & Co., Inc. |
Novel 1,8-naphthyridine compounds
|
|
US8063037B2
(en)
|
2007-05-07 |
2011-11-22 |
N. V. Organon |
Progesterone receptor modulators
|
|
WO2010077915A1
(en)
|
2008-12-17 |
2010-07-08 |
Forest Laboratories Holdings Limited |
Novel compounds useful as cc chemokine receptor ligands
|
|
GB0910493D0
(en)
|
2009-06-17 |
2009-07-29 |
Ucb Pharma Sa |
Therapeutic agents
|
|
US8816074B2
(en)
|
2009-11-16 |
2014-08-26 |
University of Georgia Foundation, Inc. |
2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
|
|
AP2012006535A0
(en)
|
2010-03-31 |
2012-10-31 |
Gilead Pharmasset Llc |
Stereoselective synthesis of phosphorous containing actives
|
|
CN103889428A
(zh)
|
2010-10-04 |
2014-06-25 |
肝炎与病毒研究所 |
乙型肝炎病毒抗原分泌的新型抑制剂
|
|
PT2726613T
(pt)
|
2011-06-30 |
2018-10-26 |
Arrowhead Pharmaceuticals Inc |
Composições e métodos para inibição da expressão de genes do vírus da hepatite b
|
|
WO2013006394A1
(en)
|
2011-07-01 |
2013-01-10 |
Institute For Hepatitis And Virus Research |
Sulfamoylbenzamide derivatives as antiviral agents against hbv infection
|
|
EP2794565B1
(en)
|
2011-12-21 |
2017-07-26 |
Novira Therapeutics Inc. |
Hepatitis b antiviral agents
|
|
NZ631419A
(en)
|
2012-02-29 |
2017-03-31 |
Baruch S Blumberg Inst |
Inhibitors of hepatitis b virus covalently closed circular dna formation and their method of use
|
|
US20130267517A1
(en)
|
2012-03-31 |
2013-10-10 |
Hoffmann-La Roche Inc. |
Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
|
|
MX2014011749A
(es)
|
2012-03-31 |
2015-01-22 |
Hoffmann La Roche |
4-metil-dihidropirimidinas novedosas para el tratamiento y la prolifaxis de la infeccion por el virus de la hepatitis b.
|
|
CA2881057C
(en)
|
2012-08-28 |
2020-10-27 |
Janssen Sciences Ireland Uc |
Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
|
|
NZ704758A
(en)
|
2012-08-28 |
2018-06-29 |
Janssen Sciences Ireland Uc |
Fused bicyclic sulfamoyl derivatives and the use thereof as medicaments for the treatment of hepatitis b
|
|
CN104918612B
(zh)
|
2012-12-06 |
2019-10-25 |
巴鲁克斯布隆伯格研究所 |
作为抗hbv感染的抗病毒剂的官能化苯甲酰胺衍生物
|
|
HK1217649A1
(zh)
|
2012-12-27 |
2017-01-20 |
德雷克塞尔大学 |
針對hbv感染的新型抗病毒劑
|
|
JP6466348B2
(ja)
|
2013-02-28 |
2019-02-06 |
ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー |
スルファモイル−アリールアミドおよびｂ型肝炎を処置するための医薬品としてのその使用
|
|
US8993771B2
(en)
|
2013-03-12 |
2015-03-31 |
Novira Therapeutics, Inc. |
Hepatitis B antiviral agents
|
|
HUE033542T2
(en)
|
2013-04-03 |
2017-12-28 |
Janssen Sciences Ireland Uc |
Their use as medicaments for the treatment of N-phenylcarboxamide derivatives and hepatitis B
|
|
HUE040446T2
(hu)
|
2013-05-17 |
2019-03-28 |
Janssen Sciences Ireland Uc |
Szulfamoiltiofenamid-származékok és gyógyszerként történõ alkalmazásuk hepatitis B kezelésére
|
|
TW202126620A
(zh)
|
2013-05-17 |
2021-07-16 |
愛爾蘭商健生科學愛爾蘭無限公司 |
胺磺醯基吡咯醯胺衍生物及其作為用於治療ｂ型肝炎藥物的用途
|
|
WO2015011281A1
(en)
|
2013-07-25 |
2015-01-29 |
Janssen R&D Ireland |
Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
|
|
MX368158B
(es)
|
2013-10-23 |
2019-09-20 |
Janssen Sciences Ireland Uc |
Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
|
|
CA2928003A1
(en)
|
2013-11-14 |
2015-05-21 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis b infections
|
|
US9169212B2
(en)
|
2014-01-16 |
2015-10-27 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis B infections
|
|
PE20160686A1
(es)
*
|
2014-01-30 |
2016-07-23 |
Hoffmann La Roche |
Nuevas dihidroquinolizinonas para el tratamiento y profilaxis de la infeccion por virus de la hepatitis b
|
|
PL3102572T3
(pl)
|
2014-02-06 |
2019-04-30 |
Janssen Sciences Ireland Uc |
Pochodne sulfamoilopirolamidu i ich zastosowanie jako leki do leczenia wirusowego zapalenia wątroby typu B
|
|
PL3114128T3
(pl)
|
2014-03-07 |
2019-06-28 |
F. Hoffmann-La Roche Ag |
Nowe skondensowane w pozycji 6 heteroarylodihydropirymidyny stosowane w leczeniu i profilaktyce zakażenia wirusem zapalenia wątroby typu B
|
|
ES2748029T3
(es)
|
2014-03-13 |
2020-03-12 |
Univ Indiana Res & Tech Corp |
Moduladores alostéricos de proteína núcleo de hepatitis B
|
|
CN106459032B
(zh)
*
|
2014-05-13 |
2019-04-05 |
豪夫迈·罗氏有限公司 |
治疗和预防乙型肝炎病毒感染的新的二氢喹嗪酮类
|
|
EP3150600B1
(en)
|
2014-05-30 |
2018-06-27 |
Qilu Pharmaceutical Co., Ltd. |
Dihydropyrimido loop derivative as hbv inhibitor
|
|
JP6506836B2
(ja)
|
2014-08-14 |
2019-04-24 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
Ｂ型肝炎ウイルス感染症の処置および予防のための新規ピリダゾンおよびトリアジノン
|
|
US10415037B2
(en)
*
|
2014-10-02 |
2019-09-17 |
Arbutus Biopharma Corporation |
Compositions and methods for silencing hepatitis B virus gene expression
|
|
US9637485B2
(en)
|
2014-11-03 |
2017-05-02 |
Hoffmann-La Roche Inc. |
6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection
|
|
CN107406378A
(zh)
|
2014-12-02 |
2017-11-28 |
诺维拉治疗公司 |
用于hbv治疗的硫化烷基化合物和吡啶类反式磺酰胺化合物
|
|
EP3240537B1
(en)
|
2014-12-30 |
2020-09-09 |
F. Hoffmann-La Roche AG |
Novel tetrahydropyridopyrimidines and tetrahydropyridopyridines for the treatment and prophylaxis of hepatitis b virus infection
|
|
JP6435054B2
(ja)
|
2015-02-11 |
2018-12-05 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
Ｂ型肝炎ウイルス感染の治療及び予防のための新規２−オキソ−６，７−ジヒドロベンゾ［ａ］キノリジン−３−カルボン酸誘導体
|
|
JP6462155B2
(ja)
|
2015-05-04 |
2019-01-30 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
Ｂ型肝炎ウイルス感染症の治療用のＨＢｓＡｇ（ＨＢＶ表面抗原）及びＨＢＶ ＤＮＡ産生の阻害剤としてのテトラヒドロピリドピリミジン類及びテトラヒドロピリドピリジン類
|
|
US10738035B2
(en)
|
2015-05-13 |
2020-08-11 |
Enanta Pharmaceuticals, Inc. |
Hepatitis B antiviral agents
|
|
WO2017011552A1
(en)
|
2015-07-13 |
2017-01-19 |
Enanta Pharmaceuticals, Inc. |
Hepatitis b antiviral agents
|
|
EP3325477B1
(en)
*
|
2015-07-21 |
2019-05-01 |
H. Hoffnabb-La Roche Ag |
Novel tricyclic 4-pyridone-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection
|
|
WO2017015451A1
(en)
|
2015-07-22 |
2017-01-26 |
Enanta Pharmaceuticals, Inc. |
Hepatitis b antiviral agents
|
|
WO2017016960A1
(en)
|
2015-07-24 |
2017-02-02 |
F. Hoffmann-La Roche Ag |
Process for the preparation of (6s)-6-alkyl-10-alkoxy-9-(substituted alkoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid analogues
|
|
WO2017016921A1
(en)
|
2015-07-24 |
2017-02-02 |
F. Hoffmann-La Roche Ag |
New crystalline forms of (6s)-10-methoxy-6-isopropyl-9-(3-methoxypropoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid
|
|
JP6506880B2
(ja)
|
2015-07-27 |
2019-04-24 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
Ｂ型肝炎ウィルス感染症の治療および予防のための新規な四環式４−オキソ−ピリジン−３−カルボン酸誘導体
|
|
JP6559324B2
(ja)
|
2015-07-28 |
2019-08-14 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
Ｂ型肝炎ウイルス感染の治療及び予防用の新規６，７−ジヒドロピリド［２，１−ａ］フタラジン−２−オン類
|
|
TWI730985B
(zh)
|
2015-09-15 |
2021-06-21 |
美商艾森伯利生物科學公司 |
B型肝炎核心蛋白質調節劑
|
|
WO2017064156A1
(en)
|
2015-10-16 |
2017-04-20 |
F. Hoffmann-La Roche Ag |
Novel 6-fused and 2-heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
|
|
WO2017102648A1
(en)
|
2015-12-15 |
2017-06-22 |
F. Hoffmann-La Roche Ag |
Combination therapy of an hbsag inhibitor and a nucleos(t)ide analogue
|
|
WO2017108630A1
(en)
|
2015-12-21 |
2017-06-29 |
F. Hoffmann-La Roche Ag |
Combination therapy of an hbsag inhibitor and an hbv capsid assembly inhibitor
|
|
WO2017114812A1
(en)
|
2015-12-29 |
2017-07-06 |
F. Hoffmann-La Roche Ag |
Combination therapy of an hbsag inhibitor and an interferon
|
|
CN109071447B
(zh)
*
|
2016-02-19 |
2022-04-22 |
诺华股份有限公司 |
四环吡啶酮化合物作为抗病毒剂
|
|
WO2017216686A1
(en)
|
2016-06-16 |
2017-12-21 |
Novartis Ag |
8,9-fused 2-oxo-6,7-dihydropyrido-isoquinoline compounds as antivirals
|
|
WO2017216685A1
(en)
|
2016-06-16 |
2017-12-21 |
Novartis Ag |
Pentacyclic pyridone compounds as antivirals
|
|
CN107759585A
(zh)
*
|
2016-07-29 |
2018-03-06 |
银杏树药业(苏州)有限公司 |
一种异喹啉类化合物及其药用组合物和作为抗病毒药物的应用
|
|
WO2018019297A1
(zh)
|
2016-07-29 |
2018-02-01 |
银杏树药业(苏州)有限公司 |
异喹啉酮类化合物及其制备抗病毒药物的应用
|
|
CA3031063A1
(en)
*
|
2016-07-29 |
2018-02-01 |
Newave Pharmaceutical Inc. |
Benzo-quinolizin-2oxo carboxylic acid derivatives for the treatment of hbv infection
|
|
TW201811788A
(zh)
*
|
2016-09-09 |
2018-04-01 |
瑞士商諾華公司 |
作為抗病毒劑之多環吡啶酮化合物
|
|
JP7113009B2
(ja)
*
|
2016-11-07 |
2022-08-04 |
アービュタス バイオファーマ コーポレイション |
置換ピリジノン含有三環式化合物およびそれを使用する方法
|
|
CN106810548B
(zh)
*
|
2017-01-13 |
2019-02-15 |
苏州爱科百发生物医药技术有限公司 |
一种二氢异喹啉类化合物
|
|
CN108727378A
(zh)
*
|
2017-04-19 |
2018-11-02 |
银杏树药业(苏州)有限公司 |
新型异喹啉类化合物及其医药用途
|
|
SG10202111648YA
(en)
*
|
2017-10-05 |
2021-11-29 |
Glaxosmithkline Ip Dev Ltd |
Chemical compounds
|
|
CN111217811B
(zh)
*
|
2018-11-26 |
2024-01-16 |
广东东阳光药业股份有限公司 |
稠合三环类化合物及其在药物中的应用
|